Potential Antiviral Options against SARS-CoV-2 Infection.
Aleksandr IanevskiRouan YaoMona Høysæter FenstadSvetlana BizaEva ZusinaiteTuuli ReisbergHilde LysvandKirsti LøsethVeslemøy Malm LandsemJanne Fossum MalmringValentyn OksenychSten Even ErlandsenPer Arne AasLars HagenCaroline H PettersenTanel TensonJan Egil AfsetSvein Arne NordbøMagnar BjøråsDenis E KainovPublished in: Viruses (2020)
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- induced apoptosis
- cell cycle arrest
- end stage renal disease
- coronavirus disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- oxidative stress
- prognostic factors
- signaling pathway
- high throughput
- climate change
- risk assessment
- cell proliferation
- human health
- smoking cessation
- cancer stem cells
- respiratory tract